Compare DDD & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDD | FLGT |
|---|---|---|
| Founded | 1986 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 458.6M | 511.0M |
| IPO Year | 2003 | 2016 |
| Metric | DDD | FLGT |
|---|---|---|
| Price | $3.06 | $20.18 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.50 | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 242.2K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 109.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $386,902,000.00 | $18,730,000.00 |
| Revenue This Year | $1.69 | $2.80 |
| Revenue Next Year | $4.34 | $15.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.70 | $13.46 |
| 52 Week High | $4.12 | $31.04 |
| Indicator | DDD | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 43.51 | 43.26 |
| Support Level | $2.73 | $19.35 |
| Resistance Level | $3.28 | $21.56 |
| Average True Range (ATR) | 0.16 | 0.91 |
| MACD | -0.03 | -0.19 |
| Stochastic Oscillator | 34.18 | 21.84 |
3D Systems Corp provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, manufacturing and applications engineering. Its solutions support applications in two key industry verticals: Healthcare Solutions provide surgical planning, implants, instrumentation, and medical education solutions to help medical device manufacturers and healthcare providers accelerate, and ultimately, transform healthcare, and Industrial Solutions which includes aerospace, defense, transportation and general manufacturing. The company operates in the Americas, EMEA, and APAC regions.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.